Improve MEK/ERK targeting in mutant KRAS lung cancer

被引：0
|
作者：
Chen, Zhao [1 ]
Weisberg, Ellen [1 ]
Cheng, Katherine [1 ]
Kung, Andrew L. [2 ]
Bradner, James [1 ]
Griffin, James [1 ]
Wong, Kwok-Kin [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Columbia Univ, New York, NY USA
来源：
MOLECULAR CANCER RESEARCH | 2014年 / 12卷
关键词：
D O I：
10.1158/1557-3125.RASONC14-B01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B01
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer
    Yamamoto, Gaku
    Tanaka, Kosuke
    Kamata, Ryo
    Mori, Shunta
    Liu, Jie
    Yamauchi, Toyohiro
    Sakae, Yuta
    Ohashi, Akihiro
    Kobayashi, Susumu S.
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Therapeutics Targeting Mutant KRAS
    Thein, Kyaw Z.
    Biter, Amadeo B.
    Hong, David S.
    ANNUAL REVIEW OF MEDICINE, VOL 72, 2021, 2021, 72 : 349 - 364
  • [43] Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer
    Choi, Hyejin
    Deng, Jiehui
    Li, Shuai
    Silk, Tarik
    Dong, Lauren
    Brea, Elliott J.
    Houghton, Sean
    Redmond, David
    Zhong, Hong
    Boiarsky, Jonathan
    Akbay, Esra A.
    Smith, Paul D.
    Merghoub, Taha
    Wong, Kwok-Kin
    Wolchok, Jedd D.
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Interrogating MEK inhibition in a KRAS-mutant lung cancer patient-derived xenograft (PDX) resource.
    Mack, Philip C.
    Riess, Jonathan
    Burich, Rebekah A.
    Cheng, Mingshan
    Yang, Hongyuan
    Li, Yu
    Airhart, Susan D.
    Bult, Carol J.
    Keck, James G.
    Graber, Joel H.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
    Sun, Chong
    Hobor, Sebastijan
    Bertotti, Andrea
    Zecchin, Davide
    Huang, Sidong
    Galimi, Francesco
    Cottino, Francesca
    Prahallad, Anirudh
    Grernrum, Wipawadee
    Tzani, Anna
    Schlicker, Andreas
    Wessels, Lodewyk F. A.
    Smit, Egbert F.
    Thunnissen, Erik
    Halonen, Pasi
    Lieftink, Cor
    Beijersbergen, Roderick L.
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Trusolino, Livio
    Bernards, Rene
    CELL REPORTS, 2014, 7 (01): : 86 - 93
  • [46] Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition
    Deng, Jiehui
    Li, Shuai
    Herter-Sprie, Grit
    Smith, Paul A.
    Freeman, Gordon J.
    Engelman, Jeffrey A.
    Hammerman, Peter
    Wong, Kwok-Kin
    CANCER RESEARCH, 2016, 76
  • [47] PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
    Kauko, Otto
    O'Connor, Caitlin M.
    Kulesskiy, Evgeny
    Sangodkar, Jaya
    Aakula, Anna
    Izadmehr, Sudeh
    Yetukuri, Laxman
    Yadav, Bhagwan
    Padzik, Artur
    Laajala, Teemu Daniel
    Haapaniemi, Pekka
    Momeny, Majid
    Varila, Taru
    Ohlmeyer, Michael
    Aittokallio, Tero
    Wennerberg, Krister
    Narla, Goutham
    Westermarck, Jukka
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (450)
  • [48] Hope for targeted treatment of KRAS-mutant lung cancer The first clinical trial to show success at targeting KRAS mutations in lung cancer has been reported
    Crisp, Alisa
    LUNG CANCER MANAGEMENT, 2013, 2 (01) : 16 - 17
  • [49] Current therapy of KRAS-mutant lung cancer
    Ghimessy, Aron
    Radeczky, Peter
    Laszlo, Viktoria
    Hegedus, Balazs
    Renyi-Vamos, Ferenc
    Fillinger, Janos
    Klepetko, Walter
    Lang, Christian
    Dome, Balazs
    Megyesfalvi, Zsolt
    CANCER AND METASTASIS REVIEWS, 2020, 39 (04) : 1159 - 1177
  • [50] Closing the door on KRAS-mutant lung cancer
    Cully, Megan
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 747 - 747
12345